Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing...

Descripció completa

Dades bibliogràfiques

Autors principals:	Claire Vigne, Martin Dupuy, Aline Richetin, Bruno Guy, Nicholas Jackson, Matthew Bonaparte, Branda Hu, Melanie Saville, Danaya Chansinghakul, Fernando Noriega, Eric Plennevaux
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2017-09-01
Col·lecció:	Human Vaccines & Immunotherapeutics
Matèries:	dengue vaccine flaviviruses immunogenicity antibody titers antibody persistence
Accés en línia:	http://dx.doi.org/10.1080/21645515.2017.1333211
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!